St. Teresa Medical Enrolls First Patient in Surgiclot UK Clinical Trial
St. Teresa Medical has enrolled the first patient in its UK clinical trial evaluating its Surgiclot wound dressing for blood loss reduction, the St. Paul, Minn., devicemaker said Tuesday.
During the patient’s pelvic osteotomy procedure, the reduction in blood loss was significant and dramatic, says Dr. Tim Floyd, chief scientific officer. Widespread use of the product should lead to lower morbidity, shorter surgical times, lower costs, fewer transfusions and less time spent in the hospital.
CEO and co-founder Philip Messina claims Surgiclot is the only hemostatic dressing available featuring both dissolvable and resorbable qualities, dissolving in seconds to minutes while leaving behind a clot capable of achieving hemostasis in less than three minutes.
The UK’s Medicines and Healthcare products Regulatory Agency approved the 40-patient study June 18. The trial is being used to support CE Mark certification. — Jason Scott